Digesting the Glaxo decision : a difficult pill to swallow for transfer pricing practitioners

The 2008 Tax Court of Canada decision in GlaxoSmithKline provides substantial food for thought to both transfer pricing practitioners and to the Canada Revenue Agency. This article examines the decision, in particular how it applies to and impacts the standard step-by-step transfer pricing analysis prescribed by the OECD Transfer Pricing Guidelines.